Mopar Releases Sketch of Jeep® Concept
AUBURN HILLS, Mich., Oct. 29, 2020 /PRNewswire/ -- With the online SEMA360 show right around the corner, Mopar released a sketch of a concept loaded with Jeep® Performance Parts. Mopar offers more than 500 quality-tested, factory-backed parts and accessories across the entire Jeep lineup. Stay tuned.
Mopar Mopar (a simple contraction of the words MOtor and PARts) is the service, parts and customer-care brand for FCA vehicles around the globe. Born in 1937 as the name of a line of antifreeze products, the Mopar brand has evolved over more than 80 years to represent both complete care and authentic performance for owners and enthusiasts worldwide.
Mopar made its mark in the 1960s during the muscle-car era, with Mopar Performance Parts to enhance speed and handling for both road and racing use, and expanded to include technical service and customer support. Today, the Mopar brand's global reach distributes more than 500,000 parts and accessories in more than 150 markets. With more than 50 parts distribution centers and 25 customer-contact centers globally, Mopar integrates service, parts and customer-care operations in order to enhance customer and dealer support worldwide.
Complete information on the Mopar brand is available at www.mopar.com. Mopar is part of the portfolio of brands offered by global automaker Fiat Chrysler Automobiles. For more information regarding FCA (NYSE: FCAU/ MTA: FCA), please visit www.fcagroup.com.
For more information, please visit the FCA media site at http://media.fcanorthamerica.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/mopar-releases-sketch-of-jeep-concept-301162973.html
SOURCE FCA
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
- SUMMIT HOTEL PROPERTIES ANNOUNCES SECOND QUARTER 2026 EARNINGS RELEASE DATE
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NS
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Chrysler LLCSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share